Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001831942-25-000011
Filing Date
2025-08-14
Accepted
2025-08-14 17:06:37
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 10728
2 exhibit1jointfilingagreement.htm EX-1 3372
  Complete submission text file 0001831942-25-000011.txt   15947
Mailing Address 6200 LOOKOUT ROAD BOULDER CO 80301
Business Address 6200 LOOKOUT ROAD BOULDER CO 80301 720-647-8519
Enliven Therapeutics, Inc. (Subject) CIK: 0001672619 (see all company filings)

EIN.: 811523849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-91465 | Film No.: 251220824
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 444 MADISON AVENUE 35TH FLOOR NEW YORK NY 10022
Business Address 444 MADISON AVENUE 35TH FLOOR NEW YORK NY 10022 212-256-8600
Commodore Capital LP (Filed by) CIK: 0001831942 (see all company filings)

EIN.: 832659606 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A